Metabolic and Non-Metabolic Factors Determining Troglitazone Hepatotoxicity: A Review

Watkins, 1998, Hepatic dysfunction associated with troglitazone, N. Engl. J. Med., 338, 916, 10.1056/NEJM199803263381314

Gale, 2001, Lessons from the glitazones: a story of drug development, Lancet, 357, 1870, 10.1016/S0140-6736(00)04960-6

Graham, 2003, Troglitazone-induced liver failure: a case study, Am. J. Med., 114, 299, 10.1016/S0002-9343(02)01529-2

Bissell, 2001, Drug-induced liver injury: mechanisms and test systems, Hepatology, 33, 1009, 10.1053/jhep.2001.23505

Smith, 2003, Mechanisms of troglitazone hepatotoxicity, Chem. Res. Toxicol., 16, 679, 10.1021/tx034033e

Chojkier, 2005, Troglitazone and liver injury: in search of answers, Hepatology, 41, 237, 10.1002/hep.20567

Park, 2005, The role of metabolic activation in drug-induced hepatotoxicity, Annu. Rev. Pharmacol. Toxicol., 45, 177, 10.1146/annurev.pharmtox.45.120403.100058

Loi, 1999, Clinical pharmacokinetics of troglitazone, Clin. Pharmacokinet., 37, 91, 10.2165/00003088-199937020-00001

Kawai, 1997, Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs, Arzneimittelforschung, 47, 356

Honma, 2002, Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver, Drug Metab. Dispos., 30, 944, 10.1124/dmd.30.8.944

Yoshigae, 2000, Characterization of UDP-glucuronosyltransferases (UGTs) involved in the metabolism of troglitazone in rats and humans, J. Toxicol. Sci., 25, 433, 10.2131/jts.25.5_433

Watanabe, 2002, Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10, Drug Metab. Dispos., 30, 1462, 10.1124/dmd.30.12.1462

Tettey, 2001, Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo, Chem. Res. Toxicol, 14, 965, 10.1021/tx0001981

Yamazaki, 1999, Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes, Drug Metab. Dispos., 27, 1260

He, 2001, Troglitazone quinone formation catalyzed by human and rat CYP3A: an atypical CYP oxidation reaction, Biochem. Pharmacol., 62, 191, 10.1016/S0006-2952(01)00653-0

Kassahun, 2001, Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission, Chem. Res. Toxicol, 14, 62, 10.1021/tx000180q

Ramachandran, 1999, Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes, Drug Metab. Dispos., 27, 1194

Sahi, 2000, Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes, Xenobiotica, 30, 273, 10.1080/004982500237668

Prabhu, 2002, Identification of glutathione conjugates of troglitazone in human hepatocytes, Chem. Biol. Interact., 142, 83, 10.1016/S0009-2797(02)00056-X

Yamamoto, 2002, Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells, Drug Metab. Dispos., 30, 155, 10.1124/dmd.30.2.155

Lim, 2005, Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6 and CYP1A2 in pooled human liver microsomes, Drug Metab. Dispos., 33, 1211, 10.1124/dmd.104.003475

He, 2004, Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved, Drug Metab. Dispos., 32, 639, 10.1124/dmd.32.6.639

Toyoda, 2001, Toxic effect of troglitazone on cultured rat hepatocytes, Life Sci., 68, 1867, 10.1016/S0024-3205(01)00985-7

Haskins, 2001, Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes, Arch. Toxicol., 75, 425, 10.1007/s002040100251

Yamamoto, 2001, Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells, Life Sci., 70, 471, 10.1016/S0024-3205(01)01432-1

Hewitt, 2002, Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes, Chem. Biol. Interact., 142, 73, 10.1016/S0009-2797(02)00055-8

Kostrubsky, 2000, The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures, Drug Metab. Dispos., 28, 1192

Tirmenstein, 2002, Effects of troglitazone on HepG2 viability and mitochondrial function, Toxicol. Sci., 69, 131, 10.1093/toxsci/69.1.131

Vignati, 2005, An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics, Toxicology, 216, 154, 10.1016/j.tox.2005.08.003

Narayanan, 2003, Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: a flow cytometric assessment, Cytometry, 52A, 28, 10.1002/cyto.a.10011

Tolman, 2003, Hepatotoxicity of the thiazolidinediones, Clin. Liver Dis., 7, 369, 10.1016/S1089-3261(03)00020-5

Isley, 2003, Hepatotoxicity of thiazolidinediones, Expert Opin. Drug Saf., 2, 581, 10.1517/14740338.2.6.581

Lloyd, 2002, Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors, Chem. Biol. Interact., 142, 57, 10.1016/S0009-2797(02)00054-6

Gao, 2004, Identification of in vitro protein biomarkers of idiosyncratic liver toxicity, Toxicol. In Vitro, 18, 533, 10.1016/j.tiv.2004.01.012

Soglia, 2004, The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent, J. Pharm. Biomed. Anal., 36, 105, 10.1016/j.jpba.2004.04.019

Baughman, 2005, Metabolic activation of pioglitazone identified from rat and human liver microsomes and freshly isolated hepatocytes, Drug Metab. Dispos., 33, 733, 10.1124/dmd.104.002683

Bae, 2003, Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells, Mol. Pharmacol., 63, 401, 10.1124/mol.63.2.401

Bae, 2003, Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines, Toxicol. Lett., 139, 67, 10.1016/S0378-4274(02)00468-X

Kier, 2004, Applications of microarrays with toxicologically relevant genes (tox genes) for the evaluation of chemical toxicants in Sprague Dawley rats in vivo and human hepatocytes in vitro, Mutat. Res., 549, 101, 10.1016/j.mrfmmm.2003.11.015

Maniratanachote, 2005, Chaperone proteins involved in troglitazone-induced toxicity in human hepatoma cell lines, Toxicol. Sci., 83, 293, 10.1093/toxsci/kfi022

Watanabe, 2003, A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus, Clin. Pharmacol. Ther., 73, 435, 10.1016/S0009-9236(03)00014-6

Shishido, 2003, Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes, Hepatology, 37, 136, 10.1053/jhep.2003.50014

Bova, 2005, Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells, Toxicol. Lett., 155, 41, 10.1016/j.toxlet.2004.08.009

Bernardi, 1996, The permeability transition pore. Control points of a cyclosporin A-sensitive mitochondrial channel involved in cell death, Biochim. Biophys. Acta, 1275, 5, 10.1016/0005-2728(96)00041-2

Lemasters, 1998, The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy, Biochim. Biophys. Acta, 1366, 177, 10.1016/S0005-2728(98)00112-1

Masubuchi, 2002, Role of mitochondrial permeability transition in diclofenacinduced hepatocyte injury in rats, Hepatology, 35, 544, 10.1053/jhep.2002.31871

Masubuchi, 2005, Involvement of mitochondrial permeability transition in acetaminopheninduced liver injury in mice, J. Hepatol., 42, 110, 10.1016/j.jhep.2004.09.015

Masubuchi, 2006, Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones, Toxicology, 222, 233, 10.1016/j.tox.2006.02.017

Eguchi, 1997, Intracellular ATP levels determine cell death fate by apoptosis or necrosis, Cancer Res., 57, 1835

Lemasters, 1999, Mechanisms of Hepatic Toxicity. V. Necrapoptosis and the mitochondrial permeability transition: shared pathways to necrosis and apoptosis, Am. J. Physiol., 276, G1

Shiau, 2005, Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/BBcl-2 functions independently of PPARγ, Cancer Res., 65, 1561, 10.1158/0008-5472.CAN-04-1677

Yu, 2006, Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo, Hepatology, 43, 134, 10.1002/hep.20994

Gouni-Berthold, 2001, Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway, Naunyn. Schmiedebergs Arch. Pharmacol., 363, 215, 10.1007/s002100000352

Green, 1995, PPAR: a mediator of peroxisome proliferator action, Mutat. Res., 333, 101, 10.1016/0027-5107(95)00136-0

Bedoucha, 2001, Diabetic KKAy mice exhibit increased hepatic PPARγ1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones, J. Hepatol., 35, 17, 10.1016/S0168-8278(01)00066-6

Boelsterli, 2002, Toxicological consequences of altered peroxisome proliferator-activated receptor γ (PPARγ) expression in the liver: insights from models of obesity and type 2 diabetes, Biochem. Pharmacol., 63, 1, 10.1016/S0006-2952(01)00817-6

Buckingham, 2005, Thiazolidinediones: Pleiotropic drugs with potent anti-inflammatory properties for tissue protection, Hepatol. Res., 33, 167, 10.1016/j.hepres.2005.09.027

Enomoto, 2003, Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-γ, pioglitazone, J. Pharmacol. Exp. Ther., 306, 846, 10.1124/jpet.102.047217

Ohata, 2004, Pioglitazone prevents acute liver injury induced by ethanol and lipopolysaccharide through the suppression of tumor necrosis factor-alpha, Alcohol. Clin. Exp. Res., 28, 139S, 10.1097/01.ALC.0000134412.38510.F7

Tomita, 2004, Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met, Gastroenterology, 126, 873, 10.1053/j.gastro.2003.12.008

Sigrist, 2000, Downregulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes, Biochem. Pharmacol., 60, 67, 10.1016/S0006-2952(00)00299-9

Kovalovich, 2000, Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice, Hepatology, 31, 149, 10.1002/hep.510310123

Masubuchi, 2003, Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease, Biochem. Biophys. Res. Commun., 304, 207, 10.1016/S0006-291X(03)00572-2

Preininger, 1999, Acute troglitazone action in isolated perfused rat liver, Br. J. Pharmacol., 126, 372, 10.1038/sj.bjp.0702318

Funk, 2001, Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat, Mol. Pharmacol., 59, 627, 10.1124/mol.59.3.627

Funk, 2001, Toxicology, 167, 83, 10.1016/S0300-483X(01)00460-7

Nozawa, 2004, Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity, Drug Metab. Dispos., 32, 291, 10.1124/dmd.32.3.291

Kostrubsky, 2001, The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter-deficient rats, Drug Metab. Dispos., 29, 1561